FDA Approves Nexletol (bempedoic acid) to Lower LDL-Cholesterol
FDA Approves Nexletol (bempedoic acid) to Lower LDL-Cholesterol Print this page ANN ARBOR, Mich., Feb. 21, 2020 (GLOBE NEWSWIRE) — Esperion (NASDAQ:ESPR) announced today that the U.S. Food and Drug Administration (FDA) approved Nexletol™ (bempedoic acid) tablet, an oral, once-daily, non-statin (LDL-C) lowering medicine. Nexletol is indicated as an adjunct to diet and maximally tolerated… Read More »